Full Press Release Details
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms.
ZYME
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms
Key Takeaway: Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms